Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity.
OBJECTIVE
The effect of ezetimibe on blood lipids, oxidative stress, and fibrinolytic activity in hyperlipidemic patients was investigated after three months of therapy.


METHODS
Thirty hyperlipidemic patients were treated for twelve weeks with ezetimibe 10 mg/day. A healthy control group with matching age and gender was also included. Fasting blood glucose, lipid parameters, paraoxonase (PON1), protein carbonyl (PCO), oxidized LDL (oxLDL), 8-isoprostane (ISOPR), total antioxidant capacity (TAC) levels, tissue-type plasminogen activator (tPA), plasminogen activator inhibitor type-1 (PAI-1), and PAI-1/t-PA levels were evaluated.


RESULTS
Ezetimibe therapy for twelve weeks led to changes in lipid profile in accordance with the literature. Fibrinolytic activity parameters, PAI-1/tPA and tPA-1 decreased, whereas PAI-1 levels did not change significantly. Antioxidant parameters, serum PON1 activity, and TAC levels increased significantly compared with the basal values. Oxidant parameters, oxLDL, ISOPR, and PCO (which is an indicator of oxidative protein damage) decreased significantly after therapy.


CONCLUSIONS
Ezetimibe therapy has beneficial effects on fibrinolytic activity and homeostasis between oxidant and antioxidant activity in hyperlipidemic patients This may be through lowering lipid levels or other mechanisms such as decreasing insulin resistance and the pleiotropic effects of the drug.
Turfaner
Nurver
N
Cerrahpasa Medical Faculty, University of Istanbul, Turkey. nurverdi@gmail.com
Uzun
Hafize
H
Balci
Huriye
H
Ercan
Meltem A
MA
Karter
Yesari H
YH
Caner
Metin
M
Sipahioglu
Fikret
F
Genc
Habibe
H
D000328:Adult; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism; D043303:Aryldialkylphosphatase / Q000097:blood; D001384:Azetidines / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D000069438:Ezetimibe; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D028421:Isoprostanes / Q000097:blood; D008055:Lipids / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D050050:Protein Carbonylation / Q000187:drug effects; D010959:Tissue Plasminogen Activator
D000924:Anticholesteremic Agents; D000975:Antioxidants; D001384:Azetidines; D001786:Blood Glucose; D028421:Isoprostanes; D008055:Lipids; D008077:Lipoproteins, LDL; D017395:Plasminogen Activator Inhibitor 1; C099252:oxidized low density lipoprotein; D043303:Aryldialkylphosphatase; D010959:Tissue Plasminogen Activator; D000069438:Ezetimibe